A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer

Matin, F; Jeet, V; Moya, L; Selth, LA; Chambers, S; Clements, JA; Batra, J; Yeadon, T; Saunders, P; Eckert, A; Heathcote, P; Wood, G; Malone, G; Samaratunga, H; Collins, A; Turner, M; Kerr, K

A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer

Matin, F Jeet, V Moya, L Selth, LA Chambers, S

Clements, JA Batra, J Yeadon, T Saunders, P Eckert, A Heathcote, P Wood, G Malone, G Samaratunga, H Collins, A Turner, M Kerr, K

Permalink

Publication Type:: Journal Article
Citation:: Scientific Reports, 2018, 8 (1)
Issue Date:: 2018-12-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted Manuscript VersionAdobe PDF (2.7 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Matin, F	en_US
dc.contributor.author	Jeet, V	en_US
dc.contributor.author	Moya, L	en_US
dc.contributor.author	Selth, LA	en_US
dc.contributor.author	Chambers, S https://orcid.org/0000-0003-2369-6111	en_US
dc.contributor.author	Clements, JA	en_US
dc.contributor.author	Batra, J	en_US
dc.contributor.author	Yeadon, T	en_US
dc.contributor.author	Saunders, P	en_US
dc.contributor.author	Eckert, A	en_US
dc.contributor.author	Heathcote, P	en_US
dc.contributor.author	Wood, G	en_US
dc.contributor.author	Malone, G	en_US
dc.contributor.author	Samaratunga, H	en_US
dc.contributor.author	Collins, A	en_US
dc.contributor.author	Turner, M	en_US
dc.contributor.author	Kerr, K	en_US
dc.date.available	2018-03-19	en_US
dc.date.issued	2018-12-01	en_US
dc.identifier.citation	Scientific Reports, 2018, 8 (1)	en_US
dc.identifier.uri	http://hdl.handle.net/10453/129507
dc.description.abstract	© 2018 The Author(s). Prostate cancer is diagnosed in over 1 million men every year globally, yet current diagnostic modalities are inadequate for identification of significant cancer and more reliable early diagnostic biomarkers are necessary for improved clinical management of prostate cancer patients. MicroRNAs (miRNAs) modulate important cellular processes/pathways contributing to cancer and are stably present in body fluids. In this study we profiled 372 cancer-associated miRNAs in plasma collected before (∼60% patients) and after/during commencement of treatment (∼40% patients), from age-matched prostate cancer patients and healthy controls, and observed elevated levels of 4 miRNAs - miR-4289, miR-326, miR-152-3p and miR-98-5p, which were validated in an independent cohort. The miRNA panel was able to differentiate between prostate cancer patients and controls (AUC = 0.88). Analysis of published miRNA transcriptomic data from clinical samples demonstrated low expression of miR-152-3p in tumour compared to adjacent non-malignant tissues. Overexpression of miR-152-3p increased proliferation and migration of prostate cancer cells, suggesting a role for this miRNA in prostate cancer pathogenesis, a concept that was supported by pathway analysis of predicted miR-152-3p target genes. In summary, a four miRNA panel, including miR-152-3p which likely targets genes with key roles in prostate cancer pathogenesis, has the potential to improve early prostate cancer diagnosis.	en_US
dc.relation.ispartof	Scientific Reports	en_US
dc.relation.isbasedon	10.1038/s41598-018-24424-w	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Prostatic Neoplasms	en_US
dc.subject.mesh	MicroRNAs	en_US
dc.subject.mesh	Male	en_US
dc.subject.mesh	Biomarkers, Tumor	en_US
dc.title	A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer	en_US
dc.type	Journal Article
utslib.citation.volume	1	en_US
utslib.citation.volume	8	en_US
utslib.for	0601 Biochemistry and Cell Biology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	open_access
pubs.issue	1	en_US
pubs.publication-status	Published	en_US
pubs.volume	8	en_US

Abstract:

© 2018 The Author(s). Prostate cancer is diagnosed in over 1 million men every year globally, yet current diagnostic modalities are inadequate for identification of significant cancer and more reliable early diagnostic biomarkers are necessary for improved clinical management of prostate cancer patients. MicroRNAs (miRNAs) modulate important cellular processes/pathways contributing to cancer and are stably present in body fluids. In this study we profiled 372 cancer-associated miRNAs in plasma collected before (∼60% patients) and after/during commencement of treatment (∼40% patients), from age-matched prostate cancer patients and healthy controls, and observed elevated levels of 4 miRNAs - miR-4289, miR-326, miR-152-3p and miR-98-5p, which were validated in an independent cohort. The miRNA panel was able to differentiate between prostate cancer patients and controls (AUC = 0.88). Analysis of published miRNA transcriptomic data from clinical samples demonstrated low expression of miR-152-3p in tumour compared to adjacent non-malignant tissues. Overexpression of miR-152-3p increased proliferation and migration of prostate cancer cells, suggesting a role for this miRNA in prostate cancer pathogenesis, a concept that was supported by pathway analysis of predicted miR-152-3p target genes. In summary, a four miRNA panel, including miR-152-3p which likely targets genes with key roles in prostate cancer pathogenesis, has the potential to improve early prostate cancer diagnosis.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/129507